№ files_lp_4_process_1_50326
File format: docx
Character count: 6625
File size: 20 KB
Formal medical letter documenting the clinical justification and insurance coverage request for hemiplegic migraine panel genetic testing with detailed patient history, clinical indications, prior testing, and gene-specific implications for treatment and management.
Year:
2026
Patient Name:
[REDACTED]
Patient DOB:
[REDACTED]
Insurance Company:
[REDACTED]
Policy Number:
[REDACTED]
Group Number:
[REDACTED]
ICD10 Codes:
[REDACTED]
Test Name:
Hemiplegic Migraine Panel
CPT Codes:
81406x1, 81407x1, 81479x1
Laboratory:
GeneDx, Inc.
Laboratory Address:
207 Perry Parkway, Gaithersburg, MD 20877
Laboratory NPI:
1487632998
Laboratory TAXID:
205446298
Laboratory CLIA:
21D0969951
Ordering Provider:
[REDACTED]
Purpose:
Request for insurance coverage for medically necessary genetic testing
Clinical Indications:
Hemiplegic migraine with aura, family and personal medical history, uninformative prior genetic tests
Relevant Genes:
CACNA1A, SCN1A, ATP1A2, PRRT2
Clinical Features:
Aura, hemiplegic attacks, ataxia, intellectual disability, risk of seizures
Inheritance Pattern:
Autosomal dominant for familial hemiplegic migraine
Target Population:
Individuals with hemiplegic migraine symptoms and family history of similar disorders
References:
Albury et al. 2017; Huang et al. 2017; Pelzer et al. 2018; Jen JC 2001/2015; Noebels et al. 2012; Ebrahimi-Fakhari et al. 2015; Riant et al. 2010
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2019–2020
Region / country:
Australia
Subject:
Chronic migraine treatment and drug listing
Document type:
Public Summary Document (PSD)
Organization / authority:
Pharmaceutical Benefits Advisory Committee (PBAC), TGA
Drug:
Galcanezumab (Emgality)
Other drugs referenced:
Fremanezumab, Erenumab, Botox
Target population:
Adults with chronic migraine unresponsive to at least three prophylactic migraine medications
Administration form:
Injection 120 mg/1 mL pre-filled pen
Prescription restrictions:
Streamlined listing, treatment by neurologist required, specific clinical criteria for migraine frequency and prior treatment response
Consumer input:
Included 186 individuals, 2 health professionals, 1 organization
Cost analysis:
Cost-minimisation analysis (CMA) versus Botox
Risk sharing arrangement:
Included, with expenditure cap adjustments
Date:
[Date]
Patient:
[Patient’s First and Last Name]
Date of Birth:
[Patient’s Date of Birth]
Insurance Company:
[Insurance Company Name]
Subscriber ID #:
[Insurance Subscriber ID]
Subscriber Group #:
[Insurance Group ID]
Insurance Company Contact:
[Insurance Company Contact]
Insurance Company Address:
[Insurance Company Address]
Insurance Company City, State ZIP:
[Insurance Company City, State ZIP]
Medication:
VYEPTI® (eptinezumab-jjmr) [100 mg/300 mg]
Indication:
Preventive treatment of chronic/episodic migraine
ICD-10 Code:
[ICD-10 code]
Prior Treatments:
[List prior treatments with dates and reasons for discontinuation]
Dose Initiation:
[100 mg/300 mg]
Dose Escalation:
[If applicable, 300 mg]
Treatment Continuation:
[Current VYEPTI dose and response]
Physician:
[Physician’s Name]
Provider Identification Number:
[Provider Identification Number]
Practice Name:
[Name of Practice]
Practice Phone Number:
[Phone Number]
Enclosures:
Original Letter of Medical Necessity, patient clinical/diagnostic notes, relevant lab reports, published clinical references
Category:
Health Condition/ Disease
Subcategory:
Intervention
Last Updated:
2014-03-11
Keywords:
headache, migraine, attack, migrainous head pain, aura, neurological disorder, nervous system
Evidence:
B, C & D
Grade of Evidence:
B, C & D
Context:
A systematic review and critical analysis of dietary components that are self-reported as triggers for migraines, based on cross-sectional, case-control, experimental, and cohort studies.
Year:
2024
Location:
Tangent Theater, Trinity College Dublin, Ireland
Theme:
Clinical Neurology, Headache Disorders
Document type:
Conference Program
Organizing body:
Trinity College Dublin
Course director:
Dr Anhar Hassan
Speakers:
Prof Anhar Hassan, Ms Helen Cahill, Prof Miriam Galvin, Ms Naomi Thornton, Ms Sharon Moran, Dr Petya Mihaylova, Dr Siobhan Hutchinson, Ms Mary Pilladath, Dr Eddie O’Sullivan, Dr Nicholas Silver, Prof Brian McGuire
Target audience:
Healthcare professionals, neurologists, clinicians
Date:
February 2, 2024
Schedule:
09:00–16:30
Sessions:
Registration, Welcome, Keynote lectures, Panel discussions, Coffee breaks, Lunch, Closing remarks
Context:
Detailed agenda of a professional neurology conference including lectures, discussions, and practical sessions on migraine and other headache disorders
Year:
2023
Region / City:
Global
Topic:
Migraine Treatment and Prophylaxis
Document Type:
Pharmaceutical List
Author:
Not specified
Target Audience:
Healthcare professionals
Period of validity:
Ongoing
Approval Date:
Not specified
Date of modifications:
Not specified
Note:
Year
Theme:
Medical Equipment, Adaptive Devices
Document Type:
Medical Necessity Letter
Target Audience:
Insurance Providers, Medical Professionals
Organization:
Driscoll Health Plan
Document type:
Clinical policy and administrative guidelines
Revision date:
November 1, 2024
Geographic scope:
Texas
Programs referenced:
STAR, STAR Kids, CHIP
Subject area:
Therapy services prior authorization and medical necessity
Target audience:
Therapy providers and referring physicians
Authorization method:
Provider web portal and fax submission
Related forms:
Texas Standard Prior Authorization Request Form for Health Care Services (TARF), Therapy Referral Review by Ordering Physician Attestation Form
Effective policy elements:
Initial evaluations, re-evaluations, continuation of therapy, start of care rules
Coverage criteria:
Medical necessity based on clinical documentation
Source type:
Health plan policy guideline
Year:
2021
Region / City:
United States
Topic:
Medical Necessity Letter, Health Treatment
Document Type:
Medical Document
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Medical professionals, healthcare providers
Period of validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2021
Region / City:
California, Arizona
Topic:
Energy Transmission, Public Utilities
Document Type:
Decision
Organization / Institution:
California Public Utilities Commission
Author:
California Public Utilities Commission
Target Audience:
Stakeholders in energy infrastructure and transmission
Effective Period:
N/A
Approval Date:
November 4, 2021
Date of Changes:
N/A
Year:
2025
Region / City:
United States
Theme:
Medical necessity letter
Document type:
Medical letter
Organization / Institution:
Takeda Pharmaceuticals U.S.A., Inc.
Author:
Takeda Pharmaceuticals U.S.A., Inc.
Target audience:
Physicians, insurance providers
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Note:
Date
Diagnosis:
G36.0, neuromyelitis optica [Devic]
Treatment:
UPLIZNA® (inebilizumab-cdon), injection, 1 mg
Reason for request:
Medical necessity for treatment of neuromyelitis optica spectrum disorder (NMOSD) with UPLIZNA
Enclosures:
Prescribing Information, clinical notes, FDA approval letter, patient relapse history, test results, etc.
Year:
2024
Region / City:
United States
Topic:
Medical Necessity Letter
Document Type:
Medical Letter
Organization / Institution:
Bausch + Lomb
Author:
Physician
Target Audience:
Healthcare providers, Payers
Action Period:
June 2024
Approval Date:
June 2024
Modification Date:
N/A
Document type:
Medical necessity letter
Therapeutic area:
Ophthalmology
Indication:
Reduction of intraocular pressure in open-angle glaucoma or ocular hypertension
Medication name:
VYZULTA (latanoprostene bunod ophthalmic solution)
Dosage strength:
0.024%
Drug class:
Prostaglandin analogue with nitric oxide–donating activity
Regulatory status:
FDA-approved prescription medication
Manufacturer:
Bausch & Lomb Inc.
Intended recipient:
Health insurance payer or medical director
Target population:
Patients with open-angle glaucoma or ocular hypertension
Clinical evidence referenced:
Phase 2 VOYAGER study; Phase 3 APOLLO and LUNAR studies; real-world retrospective studies
Safety information included:
Yes
References:
Peer-reviewed journals and prescribing information
Source type:
Industry-provided informational material
Year:
2025
Region / City:
Princeton, NJ
Theme:
Medical necessity documentation
Document Type:
Medical letter
Organization / Institution:
Bristol-Myers Squibb Company
Author:
<>
Target Audience:
Healthcare professionals, physicians
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2025
Jurisdiction:
West Virginia, United States
Type of document:
Legislative Act
Governing body:
West Virginia Legislature
Authors:
Delegates Riley, Linville, D. Cannon, Eldridge
Effective date:
April 11, 2025
Subject:
Public utilities regulation, water and sewer services, certificate of public convenience and necessity
Legal references:
§24-2-11, §31-15A-1 et seq. of the West Virginia Code
Scope:
Construction projects of water and sewer services for utilities with at least 4,500 customers and $3 million or more in annual revenues
Approval authority:
Public Service Commission, Infrastructure and Jobs Development Council
Decision timelines:
Standard projects 225–270 days, projects >$50 million 400 days
Year:
2023
Region / City:
United States
Subject:
Healthcare
Document Type:
Template
Institution / Organization:
Takeda Oncology
Author:
Takeda Oncology
Target Audience:
Healthcare providers, insurance companies
Effective Period:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Note:
Date
Year:
2026
Region / City:
N/A
Topic:
Genetic Testing, Exome Sequencing
Document Type:
Letter
Organization / Institution:
N/A
Author:
N/A
Target Audience:
Healthcare providers, medical practitioners
Validity Period:
N/A
Approval Date:
N/A
Modification Date:
N/A
Program:
Illinois Early Intervention Program
State:
Illinois
Type of document:
Administrative form
Subject area:
Early intervention services
Focus:
Assistive technology justification
Target population:
Infants and toddlers enrolled in Early Intervention
Associated plan:
Individualized Family Service Plan (IFSP)
Required contributors:
Early Intervention evaluator, service coordinator, physician
Required approvals:
Physician signature
Content sections:
Demographic information, provider information, IFSP details, assessment and justification
Purpose:
Documentation of developmental necessity for assistive technology items
Note:
Year
Topic:
Medical Nutrition
Document Type:
Template Letter
Organization / Institution:
Abbott Nutrition
Author:
Physician
Target Audience:
Health Insurance Providers